AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm

 AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm

AstraZeneca to Divest Worldwide Commercialization Rights of Losec (omeprazole) to Cheplapharm

Shots:

  • AstraZeneca to receive upfront, $243M on completion of the agreement with ~33M as a commercial milestone in 2021 and 2022. Cheplapharm to get global commercial rights for Losec & associated brands (Acimax, Antra, Mepral, Mopral, Omepral and Zoltum) excluding the US, China, Japan & Mexico
  • The agreement allows AstraZeneca to focus on its three main therapeutic areas while it continues to manufacture, supply & commercialize the therapy where it holds the rights
  • Losec is a proton pump inhibitor, helps to reduce the amount of acid produced by the stomach in patients with GERD & ulcers

Click here to­ read full press release/ article | Ref: AstraZeneca| Image: China Daily

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post